
    
      This is a Phase I study of human neural stem cell transplantation for the treatment of
      chronic motor stroke. This single-site, Phase I, open-label study may enroll up to 18
      patients across 5 cohorts of ascending doses of human neural stem cells to define maximal
      tolerated dose.
    
  